Key result
Functional mushrooms lower preclinical blood pressure via ACE inhibition, but human trial evidence remains limited.
Why the study?
Suboptimal blood pressure control and adverse effects from antihypertensive medications have stimulated interest in complementary strategies such as functional mushrooms, which contain bioactive compounds capable of modulating pathways involved in blood pressure regulation.
Do selected functional mushrooms and their bioactive compounds reduce blood pressure and support hypertension management?
Do selected functional mushrooms and their bioactive compounds reduce blood pressure and support hypertension management?
Functional mushrooms exhibit promising antihypertensive mechanisms such as ACE inhibition in preclinical models, but standardized randomized controlled trials are required before clinical adoption.
Answers are grounded in this paper and cite their sources.
Limited human data preclude clinical recommendations; leaves open the need for standardized RCTs to validate preclinical ACE inhibition.
Background: Hypertension remains one of the leading causes of cardiovascular morbidity and mortality worldwide. Despite the availability of effective antihypertensive medications, blood pressure control remains suboptimal in many patients, and adverse effects associated with pharmacotherapy have stimulated interest in complementary therapeutic strategies. Functional mushrooms are a rich source of bioactive compounds capable of modulating multiple molecular pathways involved in blood pressure regulation and therefore represent promising candidates for cardiovascular prevention. Aim of the study: This narrative review critically summarizes the current evidence regarding the antihypertensive potential of selected functional mushrooms by integrating mechanistic, in vitro, preclinical, and clinical findings. Particular emphasis is placed on the biological mechanisms underlying their activity, the quality of the available evidence, methodological limitations, and factors influencing the clinical translation of experimental findings. Material and methods: A literature search was conducted in January 2026 using PubMed and Google Scholar. Eligible publications included mechanistic studies, in vitro experiments, animal studies, human clinical trials, and relevant review articles investigating the effects of selected functional mushrooms on blood pressure regulation and related cardiovascular pathways. Results: Research identifies angiotensin-converting enzyme inhibition as the primary antihypertensive mechanism, with many mushroom-derived peptides (e.g., WALKGYK from T. matsutake and APPLRP from G. frondosa) acting as non-competitive or mixed-type inhibitors. Other identified mechanisms include enhancing nitric oxide bioavailability through the inhibition of arginase and acetylcholinesterase, and stimulating natriuresis via the Corin–ANP pathway. Animal studies consistently demonstrate reductions in systolic blood pressure and improvements in vascular remodeling. Human clinical evidence remains limited and inconsistent, and methodological heterogeneity together with insufficient standardization of mushroom preparations emerged as the principal barriers to clinical translation. Conclusions: Functional mushrooms represent a promising source of bioactive compounds with potential complementary applications in hypertension management. However, current evidence is supported predominantly by mechanistic and preclinical studies, whereas robust clinical confirmation remains insufficient. Future well-designed randomized controlled trials using chemically characterized and standardized mushroom preparations are essential to establish their efficacy, safety, and potential role in evidence-based hypertension management.
No takes yet. Share an insight, caveat, or question.
Wabiszczewicz et al. (2026) conducted a review in Hypertension. Selected functional mushrooms (including T. matsutake and G. frondosa) was evaluated on Blood pressure regulation (systolic blood pressure reduction and ACE inhibition). Functional mushrooms lower systolic blood pressure in animal models primarily via ACE inhibition, though human clinical evidence remains limited and inconsistent.
Synapse has enriched 10 related papers. Consider them for comparative context: